Vonoprazan-amoxicillin dual therapy improves 14-day eradication and reduces adverse events in patients with Helicobacter pylori infection: an updated landmark systematic review and meta-analysis of 11 randomized trials with subgroup analysis.
- DOI
- 10.20524/aog.2026.1033
- Published
- 2026 May-Jun
- Container
- Annals of gastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.20524/aog.2026.1033,
title = {Vonoprazan-amoxicillin dual therapy improves 14-day eradication and reduces adverse events in patients with Helicobacter pylori infection: an updated landmark systematic review and meta-analysis of 11 randomized trials with subgroup analysis.},
author = {Bharia U and Goel A and Raja F and Palaniswamy G and Gadde KS and Joseph E and Gupta I and Kumar SU and Shah IP and Chowdhury A and Patel H and Shah KM and Veldi VDK and Das A},
year = {2026},
journal = {Annals of gastroenterology},
doi = {10.20524/aog.2026.1033},
url = {https://doi.org/10.20524/aog.2026.1033}
}RIS
TY - JOUR TI - Vonoprazan-amoxicillin dual therapy improves 14-day eradication and reduces adverse events in patients with Helicobacter pylori infection: an updated landmark systematic review and meta-analysis of 11 randomized trials with subgroup analysis. AU - Bharia U AU - Goel A AU - Raja F AU - Palaniswamy G AU - Gadde KS AU - Joseph E AU - Gupta I AU - Kumar SU AU - Shah IP AU - Chowdhury A AU - Patel H AU - Shah KM AU - Veldi VDK AU - Das A PY - 2026 JO - Annals of gastroenterology DO - 10.20524/aog.2026.1033 UR - https://doi.org/10.20524/aog.2026.1033 ER -
APA
U, B., A, G., F, R., G, P., KS, G., E, J., I, G., SU, K., IP, S., A, C., H, P., KM, S., VDK, V., & A, D. (2026). Vonoprazan-amoxicillin dual therapy improves 14-day eradication and reduces adverse events in patients with Helicobacter pylori infection: an updated landmark systematic review and meta-analysis of 11 randomized trials with subgroup analysis.. Annals of gastroenterology. https://doi.org/10.20524/aog.2026.1033
Source records
- pubmed · retrieved 2026-09-27T08:45:19.669Z